Jaypirca là gì?

Jaypirca is an anticancer medication, also known by the name of the active component it contains: pirtobrutinib. This medication was recently granted accelerated approval by the FDA for treating refractory or relapsed mantle cell lymphoma (MCL), a form of non-Hodgkin’s lymphoma (NHL), in adult patients. As an accelerated approval medication, Jaypirca fills a medical need for MCL that other medication therapies currently do not meet.  However, in order to obtain regular FDA approval, the drug company must complete clinical trials to further confirm the clinical benefit of this medication.

Jaypirca (pirtobrutinib) belongs to the drug class called “BTK inhibitors,” which block the activity of the BTK enzyme and inhibit the abnormal growth of B-cells in MCL. Jaypirca is unique in that it is a non-covalent inhibitor, whereas other treatments for MCL on the market are covalent inhibitors. As a non-covalent inhibitor, Jaypirca targets specific BTK mutations that are becoming resistant to the covalent inhibitors.